An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis

Clinical Therapeutics

Volumn 24, Issue 12, 2002, Pages 2105-2122

  Weiss, Karl ^a   Vanjaka, Anita ^b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b Abbott Canada   (Canada)

Author keywords

Acute exacerbation of chronic bronchitis; Clarithromycin; Extended release; Immediate release; Treatment

Indexed keywords

CLARITHROMYCIN;

ABDOMINAL PAIN; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TABLET; TASTE DISORDER; TREATMENT OUTCOME;

EID: 0036931776     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80100-X     Document Type: Article

References (26)

1. Woolcock AJ. Epidemiology of chronic airways disease. Chest. 1989;96(Suppl):302S-306S.
2. Lacasse Y, Brooks D, Goldstein RS. Trends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic Society. Chest. 1999;116:306-313.
3. Skudlarska BA, Scott GC. The role of antibiotics in the management of acute exacerbation of chronic bronchitis (answers to some commonly asked questions). Mo Med. 1992;89:289-293.
4. Ball P. Epidemiology and treatment of chronic bronchitis and its exaerbations. Chest. 1995;108(Suppl):43S-52S.
5. Tager I, Speizer FE. Role of infection in chronic bronchitis. N Engl J Med. 1975;292:563-571.
6. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis. 1992;15:757-761.
7. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med. 1982;97:18-21.
8. Bates JH. The role of infection during exacerbations of chronic bronchitis. Ann Intern Med. 1982;97:130-131.
9. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A metaanalysis. JAMA. 1995;273:957-960.
10. Destache CJ, Dewan N, O'Donohue WJ. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;43(Suppl A):107-113.
11. Barry AL, Fuchs PC, Brown SD. Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics. J Antimicrob Chemother. 1995;35:552-555.
12. Williams JD, Sefton AM. Comparison of macrolide antibiotics. J Antimicrob Chemother. 1993;31(Suppl C):11-26.
13. Aldons PM. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother. 1991;27(Suppl A):101-108.
14. Adam D. Clarithromycin 250 mg b.i.d. for 5 or 10 days in the treatment of adult patients with purulent bronchitis. Infection. 1993;21:265-271.
15. Vincken W, Yernault JC. Efficacy and tolerability of clarithromycin versus azithromycin in the short-course treatment of acute bronchitis. Drug Invest. 1993;6:170-175.
16. Wettengel R, Vetter N, Waardenburg FA. Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis. J Antimicrob Chemother. 1993;31:963-972.
17. Pozzi E, Grossi E, Pecori A, and the Azithromycin Research Group. Azithromycin versus clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Curr Ther Res Clin Exp. 1994;55:759-764.
18. Hosie J, Quinn P, Smits P, Sides G. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother. 1995;36:173-183.
19. Guay DR, Gustavson LE, Devcich KJ, et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther. 2001;23:566-577.
20. Adler JL, Jannetti W, Schneider D, et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin Ther. 2000;22:1410-1420.
21. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
22. Rachelefsky GS, Katz RM, Siegel SC. A sustained release theophylline preparation: Efficacy in childhood asthma with low serum theophylline levels. Ann Allergy. 1978;40:252-257.
23. US Department of Health and Human Services. Guidance for Industry: Acute Bacterial Exacerbations of Chronic Bronchitis - Developing Antimicrobial Drugs for Treatment. Rockville, Md: Food and Drug Administration, Center for Drug Evaluation and Research; 1998.
24. Chapin K. Clinical microbiology. In: Murray PR, ed. Manual of Clinical Microbiology. 6th Ed. Washington, DC: American Society for Microbiology; 1995:33-51.
25. Anzueto A, Fisher CL Jr, Busman T, Olson CA. Comparison of the effects of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin Ther. 2001;23:72-86.
26. Murray JJ, Solomon E, McCluskey D, et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin Ther. 2000;22:1421-1432.